Cosnahan Anna S, Campbell Christopher T
J Pediatr Pharmacol Ther. 2019 Sep-Oct;24(5):398-405. doi: 10.5863/1551-6776-24.5.398.
Patients with refractory epilepsy from inborn errors of metabolism typically present as neonates. Direct supplementation with the deficient vitamin or cofactor is recommended, and case series report both efficacy and safety data of these agents. Some conditions may also occur together, necessitating multiple treatments. Despite effective and early treatment, patients are at heightened risk for neurological sequela. The literature on seizures related to metabolic deficiencies for pediatric patients is limited but has some guidance on appropriate dosing and monitoring for agents to target specific deficiencies, which may help with narrowing antiepileptic therapies, reducing side effects, and improving neurodevelopmental outcomes and quality of life. The focus of this review is to discuss the pharmacotherapy, including the most updated published efficacy and safety data, involved in treating refractory epilepsy as a result of metabolic errors.
患有因先天性代谢缺陷导致难治性癫痫的患者通常在新生儿期发病。建议直接补充缺乏的维生素或辅助因子,病例系列报告了这些药物的疗效和安全性数据。某些情况也可能同时出现,需要多种治疗方法。尽管进行了有效且早期的治疗,但患者仍有更高的神经后遗症风险。关于儿科患者与代谢缺陷相关癫痫发作的文献有限,但对于针对特定缺陷的药物的适当剂量和监测有一些指导意见,这可能有助于缩小抗癫痫治疗范围、减少副作用,并改善神经发育结局和生活质量。本综述的重点是讨论用于治疗因代谢错误导致的难治性癫痫的药物治疗,包括最新发表的疗效和安全性数据。